Advertising zone 8

NLS asked the CEO and co-founder of Pixelgen about entrepreneurship in Sweden, the company’s global commercialization strategy and the most exciting clinical applications of the company’s Proxiome kit.

Researchers at the University of Turku, working with France’s Gustave Roussy Institute, have identified a molecular mechanism that lets an aggressive subtype of colorectal cancer shield itself from chemotherapy and spread through the abdominal cavity – and shown that antibodies already used against other cancers can disrupt the process.

ALK-Abelló has appointed Jacob Glenting as Executive Vice President and head of Global R&D, effective 1 September.

The US FDA has proposed reclassifying blue light cystoscopy (BLC) systems used with Photocure’s imaging agent Cysview for bladder cancer detection from Class III to Class II, a move the Norwegian medtech company says will support wider adoption of the technology in US hospitals.